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that these compounds can affect a wide range of neuroblastomas. Our experiments also revealed that
several signaling pathways underlie the selective elimination of neuroblastoma cells by the ST013381 and
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effect in vitro as promising agents for the treatment of neuroblastoma.
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ABSTRACT
Neuroblastoma represents 8–10% of all child-
hood cancer cases and is responsible for 15% of
all cancer-related deaths in infants. Even
though patients with low- and intermediate-risk
disease have a good prognosis, the 5-year sur-
vival rate of the vast majority of patients with
high-risk neuroblastoma is 50%. Despite exten-
sive research efforts to find a cure for neurob-
lastoma, current treatment options are still
limited. The aim of our study was to identify
novel therapeutic compounds using high-
throughput drug screening of a small molecule
kinase inhibitor library containing 960
compounds. This screening resulted in the
identification of two compounds, ST013381
and ST022328, that showed pronounced cyto-
toxic effects in six human neuroblastoma cell
lines in vitro while having reduced effects in the
BJ-5ta control cell line. These effects were
observed in both MYCN-amplified and -non-
amplified cells, indicating that these com-
pounds can affect a wide range of neuroblas-
tomas. Our experiments also revealed that
several signaling pathways underlie the selec-
tive elimination of neuroblastoma cells by the
ST013381 and ST022328 compounds. In sum-
mary, we have identified two novel compounds
with a strong cytotoxic effect in vitro as
promising agents for the treatment of
neuroblastoma.
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Key Summary Points
Why carry out this study?
Neuroblastoma, although representing
8–10% of all childhood cancer cases,
accounts for 15% of all cancer-related
deaths in infants.
No treatment options other than
chemotherapy exist for high-risk
neuroblastoma, even though the 5-year
survival rate is 50%.
We searched for novel therapeutic
compounds using high-throughput drug
screening of a small-molecule kinase
inhibitor library containing 960
compounds.
What was learned from the study?
We identified a group of compounds with
cytotoxic effects in six neuroblastoma cell
lines.
Data from validation studies on two of the
identified compounds suggest that the
cytotoxic effects are attained through
modulation of the PKA, PKC, ATM/ATR,
AMPK, Akt and MAPK/CDK signalling
pathways.
INTRODUCTION
Neuroblastoma is the most common extracra-
nial solid malignancy in infants and children,
with origins in sympathetic structures, such as
the adrenal glands or paraspinal sympathetic
ganglia [1]. It is usually diagnosed in children
between 1 and 2 years of age, with up to 95% of
all cases being diagnosed before 10 years of age
[2].
Although responsible for 8–10% of all
childhood malignancies, neuroblastoma
accounts for 15% of all pediatric cancer-related
deaths [3]. Patients with low-risk and interme-
diate-risk neuroblastoma usually have a very
good outcome, with 5-year overall survival rates
of 90–100%. First-line treatment of these
patients is surgical removal of the tumor, with
chemotherapy being recommended only if
residual tumor is present or excision of the
tumor is difficult [4]. Further, a subset of these
low-risk and intermediate-risk patients does not
require any treatment or surgery at all, with
spontaneous regression of the tumor even with
metastases [5]. In contrast, survival rates are
lower than 50% in patients with high-risk neu-
roblastoma [4] and, more specifically, in a small
subset of high-risk patients characterized by
high levels of either tyrosine hydroxylase (TH)
or PHOX2B mRNA in the peripheral blood, the
5-year overall survival is 0% [6]. Despite the
improvement in the 5-year overall survival for
high-risk patients over the years, from 29% in
1990 to 50% in 2010, new and improved ther-
apies are greatly needed [4].
Although neuroblastoma has a remarkably
low mutational burden, genetic alterations in
neuroblastoma have been extensively studied.
Such studies have lead to the identification of a
number of somatic mutations, including those
in anaplastic lymphoma kinase (ALK), alpha
thalassemia/mental retardation syndrome
X-linked (ATRX), v-myc avian myelocytomato-
sis viral oncogene neuroblastoma-derived
homolog (MYCN), and neuroblastoma RAS viral
oncogene homolog (NRAS) [7–10]. Germline
mutations in ALK are the main driver of familial
neuroblastoma, and somatic mutations in the
kinetic domain of this gene are found in 10% of
the sporadic cases of high-risk neuroblastoma
[9]. ALK is able to signal through the RAS-MAPK
signal transduction pathway, a pathway that is
also frequently active during relapses [11]. Loss-
of-function mutations in ATRX account for
9.6% of the cases of high-risk neuroblastoma,
increasing to 44% in adolescents or young
adults with neuroblastoma with metastatic dis-
ease. Interestingly, ATRX mutations are mutu-
ally exclusive with MYCN amplification [9, 12].
Identification and characterization of the
genetic landscape of neuroblastoma have lead
to the development and clinical applications of
various therapies targeting altered proteins. One
example is the discovery of ALK-tyrosine kinase
domain (TKI)-targeting therapies. However,
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although new ALK-TKI-targeting therapies for
non-small cell lung cancer (NSCLC) have
become available in recent years, studies on
NCLC have lead to the conclusion that new
combinatorial therapies are needed to target
secondary mutations that may arise following
the treatment of neuroblastoma with these
drugs [13].
In the study reported here, we used a high-
throughput screening technique to test a library
of 960 small-molecule kinase modulators in a
neuroblastoma cell line, followed by validation
of selected compounds in a larger neuroblas-
toma cell line cohort. To better understand the
biological effects behind the selected com-
pounds, we analyzed phosphorylation of the
kinome using the KinomeView kit (Cell Sig-
naling Technology, Beverly, MA, USA). Our data
suggest that two of the compounds identified,
ST013881 and ST022328, have cytotoxic effects
in neuroblastoma through modulation of the
PKA (protein kinase A), PKC (protein kinase C),
ATM/ATR (ataxia-telangiectasia mutated/ATM-
and Rad3-related), AMPK (50 AMP-activated






Human neuroblastoma cell lines GI-ME-N and
IGR-N-91 were kindly provided by Dr. Annick
Mühlethaler-Mottet (Lausanne University
Hospital, Lausanne, Switzerland); human neu-
roblastoma cell lines IMR-5, SH-SY5Y, and SK-N-
AS were obtained from University Children’s
Hospital Zurich; and human neuroblastoma cell
line SK-N-BE(2) and human immortalized
fibroblast cell line BJ-5ta were purchased from
the American Type Culture Collection (ATCC;
Manassas, VA, USA). Neuroblastoma cell lines
were cultured in DMEM/F-12 medium (Thermo
Fisher Scientific, Waltham, MA, USA) supple-
mented with 10% fetal bovine serum (Dutscher,
Strasbourg, France), 19 L-glutamine (Thermo
Fisher Scientific), and 19 penicillin/
streptomycin. hTERT (human telomerase
reverse transcriptase) immortalized BJ-5ta
fibroblasts were cultured in a mixture of 4 parts
of DMEM-high glucose and 1 part of medium
199, supplemented with 0.01 mg/mL hygro-
mycin B and 10% fetal bovine serum. All cells
were maintained in a humidified incubator at
37 C, 5% CO2.
High-Throughput Drug Screening
A cell-based screening was performed at NEXUS
Personalized Health Technologies (Zurich,
Switzerland). The IGR-N-91 neuroblastoma cell
line was cultured on 384-well black plates
(Greiner Bio-One GmbH, Kremsmünster, Aus-
tria) at a seeding density of 300 cells per well,
with each well containing 30 lL DMEM com-
plete media, using a BioTek EL406 peripump
(BioTek Instruments Inc., Winooski, VT, USA).
Cells were seeded on a total of eight plates, in
two batches of four plates each, in order to
avoid uneven plating of the cells along the
plates. After seeding, the plates were incubated
at 22 C for 1 h and subsequently transferred to
an incubator at 37 C, 95% humidity, and 5%
CO2. After 24 h, six plates were selected for
further use based on the homogeneity and cell
count of the plates. Compounds of the Acti-
Targ-K960 library (Timtec Inc., Newark, DE,
USA) were diluted 0.5 lL in 125 lL of DMEM
complete media, and 10-lL aliquots were
transferred to the destination plates, to reach a
final concentration of 1 and 10 lM, respec-
tively. Control edges were prepared using dox-
orubicin and etoposide at 10 lM (Selleck
Chemicals Llc, Houston, TX, USA) and DMSO
(Sigma, St. Louis, MO, USA). After 72 h of
incubation with these compounds, cell viability
was measured using the CellTiter-Glo 2.0 assay
(Promega Corp., Fitchburg, WI, USA) according
to the manufacturer’s instructions. Briefly,
CellTiter-Glo solution was brought to room
temperature, and 40 lL was added to each well
of all plates. The plates were then shaken for
5 min on a BioTek EL406 device and further
incubated at 22 C for 25 min, after which
luminescence was measured using a Tecan
M1000 Pro monochromator-based microplate
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reader (Tecan Group Ltd., Männedorf, Switzer-
land), with an integration time of 1000 ms.
Data analysis was performed using a semi-au-
tomated workflow implemented in R [37].
Compound Validation
Six neuroblastoma cell lines and one immor-
talized fibroblast cell line (see ‘‘Cell Culture’’)
were used to validate the results observed in the
high-throughput drug screening. The cell lines
were plated on 384-well black plates (Greiner
Bio-One GmbH) at a seeding density of 3000
cells per well, with each well containing 30 lL
of the respective medium, and on the following
day treated with 16 compounds at final con-
centrations ranging from 0.01 and 10 lM. After
72 h of culture, cell viability was evaluated
using the CellTiterGlo 2.0 assay, and the lumi-
nescence resulting from the reaction was mea-
sured using a Tecan Infinite 200 Pro with an
integration time of 1000 ms, as described in
‘‘High-Throughput Drug Screening’’. Data visu-
alization was performed using the software
program GraphPad Prism (GraphPad Software,
San Diego, CA, USA).
KinomeView
Cells were plated, treated for 2, 4, 6, or 12 h
with 10 lM ST013881 and ST022328, two
compounds identified from the high-through-
put screening as having cytotoxic activity in
neuroblastoma cells, and protein extracted
using RIPA buffer (Thermo Scientific, Thermo
Fisher Scientific) with 19 PhosSTOP phos-
phatase inhibitors, and 19 Omplete ULTRA
protease inhibitor cocktail (Roche AG, Basel,
Switzerland). Cell lysates were centrifuged at
14,000 rpm for 30 min at 4 C and the super-
natant collected. Protein was quantified using
the Pierce BCA assay (Thermo Scientific). Pro-
tein (30-lg samples) obtained from the cell
lysate was denatured by adding Laemmli buffer
(Bio-Rad, Hercules, CA, USA) and boiling the
samples at 95 C for 5 min. The samples were
then loaded into Mini-PROTEAN TGXTM
4–20% precast gel (Bio-Rad), electrophoresed,
and transferred onto Trans-Blot Turbo PVDF
membranes (Bio-Rad) using a Trans-Blot Turbo
Transfer System (Bio-Rad). The PVDF mem-
branes were subsequently blocked using 5%
milk for 1 h at room temperature, followed by
overnight incubation with primary antibodies
from the KinomeView kit (1:1000, Cell Signal-
ing Technology) and tubulin (1:1000; Sigma)
diluted in TBS-T (TBS with 0.1% Tween-20). The
membranes were then washed with TBS-T and
incubated for 1 h at room temperature with
secondary horseradish peroxidase-coupled
antibody (1:2000; BioLegend, San Diego, CA,
USA). After washing with TBS-T, the membranes
were developed using Clarity Western ECL
Substrate (Bio-Rad) on a Fusion Fx imaging
system (Vilber Lourmat Sté, Collégien, France).
Compliance with Ethics Guidelines
No ethical approval was required for this
research. The human cell lines used are com-
mercially available and, therefore, their use did
not require specific approval.
RESULTS
High-Throughput Screening of Small-
Molecule Kinase Modulators
To identify new compounds with cytotoxic
activity in neuroblastoma cells, we, in collabo-
ration with NEXUS Personalized Health Tech-
nologies (ETH Zürich), screened the ActiTarg-
K960 small-molecule library on the MYCN-am-
plified IGR-N-91 cell line, as MYCN amplifica-
tion represents about 25% of neuroblastoma
cases and correlates with high-risk cases
(Fig. 1a). Doxorubicin and etoposide, two
chemotherapeutics commonly used to treat
neuroblastoma, were used as positive controls
and added to both edges of the 384-well black
plates. To reduce false positives that could arise
from the treatment with only one concentra-
tion, treatments were performed at final con-
centrations of 1 and 10 lM, respectively
(Fig. 1b), and cell viability was determined after
72 h using the CellTiter-Glo 2.0 assay (Fig. 1c;
Electronic Supplementary Material [ESM]
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Fig. 1 High-throughput drug screening in the IGR-N-91
neuroblastoma cell line. a Schematic of the screening
procedure with the Acti-TargK960 small-molecule library.
b Overview of the plates in the final screen, after 72 h of
treatment with the compounds at 1 and 10 lM. c Volcano
plot of all wells (control, doxorubicin, etoposide and test
compounds). Horizontal line corresponds to a false discov-
ery rate (FDR ) = 0.01, and compounds under this line are
considered to be ‘not significant’ in terms of cytotoxic
activity. The two vertical lines correspond to a change of 0.5
in cytotoxic activity, and compounds outside this range are
considered to have ‘strong’ cytotoxic activity. dHeatmap of
the activity of 55 compounds that were considered to have
significant and strong cytotoxic activity. Doxorubicin, a
chemotherapeutic used to treat neuroblastoma, and
dimethyl sulfoxide (DMSO) were used as controls
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Table 1). The quality of the assay was verified
using the Z0-factor, and only assays with a Z0-
factor[0.5 were accepted [14]. To improve the
quality of the results, plate-to-plate systemic
variations, edge effects, and within-plate strip
patterns were removed, the first by standard
normalization procedures and the latter two by
subtracting a smooth polynomial using the
LOESS function (ESM Fig. 1, ESM Table 1)
[15–17]. From the 1920 hits observed when
testing the 960 compounds at both concentra-
tions, 141 were significantly active (false dis-
covery rate [FDR] \0.01) and 63 presented
significantly strong activity (FDR\ 0.01; nor-
malized effect size[ 0.5), corresponding to 7.3
and 3.2% of total hits, respectively. Significantly
and strongly active hits were clustered accord-
ing with their cytotoxic activity at both con-
centrations (Fig. 1d). From 55 compounds that
were considered to be significant and strongly
active (5.7% of total compounds), seven (0.7%)
showed strong cytotoxic activity at both con-
centrations (green cluster), nine (0.9%) showed
strong cytotoxic activity at 10 lM (blue cluster),
and 39 (4.0%) had mild cytotoxic activity at
10 lM (red cluster) (Fig. 1d). Sixteen com-
pounds found in the green and blue clusters
were chosen for further validation due to their
strong cytotoxic activity.
Compound Validation
Amplification of MYCN and mutations in ALK
are two of the most frequent genetic aberrations
found in neuroblastoma, present in up to 25
and 14% of sporadic cases, respectively [18]. To
achieve compound validation that would be
representative of these aberrations, we chose a
cohort of six independent neuroblastoma cell
lines (IGR-N-91, SK-N-AS, SK-N-BE(2), SH-SY5Y,
IMR-5, GI-ME-N) with varying levels of ALK and
MYCN expression. Although only SH-SY5Y pre-
sents an activating ALK F1174L mutation, SK-N-
BE(2) and IMR-5 show high expression of the
wildtype ALK gene. Cell lines SK-N-AS, IGR-N-
91, and GI-ME-N carry the wildtype ALK gene
and present no or low expression of ALK pro-
tein. In terms of MYCN amplification, SK-N-
BE(2), IGR-N-91, and IMR-5 are characterized by
MYCN gene amplification, while SK-N-AS, SH-
SY5Y, and GI-ME-N present only a single copy
of MYCN. To avoid general cytotoxicity at the
cellular level, we used one hTERT immortalized
fibroblast cell line (BJ-5ta) as a normal cell line
control for compound validation. Following
treatment of these cell lines with the test com-
pounds at concentrations of 0.01, 0.1, 1, and
10 lM, respectively, we observed that all nine
compounds belonging to the blue cluster, i.e.,
ST003148, ST012339, ST013855, ST025226,
ST033390, ST036501, ST053680, ST056969, and
ST058459, presented a lower toxicity than
doxorubicin in the BJ-5ta control cell line
(Fig. 2a). However, overall these compounds
presented a half-maximal inhibitory concen-
tration (IC50) in the six neuroblastoma cell
lines tested that was similar to IC50 observed in
the control cell line BJ-5ta, indicating possible
toxicity for normal tissues at effective treatment
concentrations (Fig. 2a; ESM Fig. 2). Following
the treatment of BJ-5ta cells with the seven
compounds from the green cluster, we observed
that the cytotoxicity of these compounds was
similar to that of doxorubicin (Fig. 2b). Also,
overall, these seven compounds showed similar
or lower IC50 in the neuroblastoma cell lines
when compared with doxorubicin, with
ST013881 presenting the best response among
all the compounds, followed in order of
decreasing IC50 by ST022328, ST024334,
ST012435, ST029265, ST024333, and ST033385
(Fig. 2b; ESM Fig. 2). Interestingly, we found
that these seven compounds could be divided
into four groups based on their structural simi-
larity, as follows: (1) ST012435 and ST013881,
which share a common phenanthroline core,
differing only on the position of the methyl
cFig. 2 Compound validation of blue and green clusters in
six neuroblastoma cell lines (IGR-N-91, SK-N-AS, SK-N-
BE(2), SH-SY5Y, IMR-5, GI-ME-N) and one control
immortalized fibroblast cell line (BJ-5ta). a Validation of
compounds from the blue cluster, b validation of
compounds from the green cluster. Data is shown as the
mean of three independent experiments ± standard devi-
ation. The dashed line represents the half-maximal
inhibitory concentration (IC50). c Chemical structure of
compounds from the green cluster
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groups; (2) ST024333 and ST024334, which
differ by the addition of two chlorine atoms
symmetrically to the structure of ST024334; (3)
ST029265 and ST033385, which share the same
core chemical structure and differ by having
either two chlorine or two bromine groups in
Fig. 3 Results of analysis using the KinomeView kit upon
treatment of IGR-N-91 with the compounds ST013881
and ST022328 identifies alterations in the PKA, PKC,
ATM/ATR, AMPK, Akt, and MAPK/CDK signaling
pathways. Immunoblotting was performed using 30 lg of
protein lysates from the IGR-N-91 cell line treated with
the ST013881 and ST022328 compounds for 2, 4, 6, and
12 h. Membranes were blocked and primary antibodies
were diluted 1:1000 in TBS-T. Upon horseradish perox-
idase (HRP)-coupled secondary antibody incubation,
membranes were developed using the Clarity Western
ECL Substrate (Bio-Rad). PKA Protein kinase A, PKC
protein kinase C, ATM/ATR ataxia-telangiectasia
mutated/ATM- and Rad3-related, AMPK 50 AMP-acti-
vated protein kinase, Akt protein kinase B, MAPK/CDK
mitogen-activated protein kinase/cyclin-dependent kinase
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the same position; and (4) ST022328 (Fig. 2c).
To study the effects on the alterations on cel-
lular phosphorylation, we selected ST013881
and ST022328 for further studies, since overall
these two compounds presented the lowest
IC50 of all the compounds analyzed.
Dissecting Cellular Phosphorylation
with KinomeView
Small-molecule kinase inhibitors can act on one
or several different kinases. A small molecule
with multiple biological targets can sometimes
be advantageous to achieve a certain therapeu-
tic aim. Therefore, with the identification of
these novel small-molecule kinase inhibitors, it
is important to better understand the biology
behind these compounds and how ST013881
and ST022328 affect signaling through specific
kinase families. Different kinase families are
able to recognize and phosphorylate specific
amino acid motifs in their downstream effec-
tors. The KinomeView kit can be used to iden-
tify not only these motifs but also a specific
serine, threonine, and tyrosine phosphorylation
pattern in a wide range of kinase families,
allowing dissection of the alterations in the
phosphoproteome following experimental
treatment. The different motifs identified by the
antibodies in the kit are specified in Fig. 3 and
ESM Fig. 2.
In this context, we treated the IGR-N-91 cell
line with the ST013881 and ST022328 com-
pounds. To ensure a sufficient inhibition of the
target kinase(s), we used the 10 lM concentra-
tion for both compounds. We evaluated the
effects of the treatment using the KinomeView
kit after 2, 4, 6, and 12 h of incubation time.
Alterations in phosphorylation were observed as
early as 2 h post-treatment. We noted that the
substrates of PKA and PKC had changed fol-
lowing ST013881 treatment and that the sub-
strates of ATM/ATR (S*Q and [S*/T*]QG motifs),
AMPK, Akt, and MAPK/CDK had been modified
following ST022328 treatment (Fig. 3). In the
case of phosphorylation in ATM/ATR substrates
(S*Q motif) by ST022328, alterations were
found as early as after 1 h of treatment (data not
shown). Interestingly, phosphorylation
alterations in MAPK/CDK substrates by
ST013881 and in PKC substrates by ST022328
were found after 6 and 12 h, respectively
(Fig. 3). No other phosphorylation alterations
were observed in the other motifs analyzed
using the KinomeView kit (ESM Fig. 3). These
observations indicate that alterations in the
phosphorylation of MAPK/CDK substrates by
ST013881 are likely a secondary outcome of the
inhibition observed after 2 h in the PKA and
PKC substrates. Similarly, alterations observed
in the phosphorylation of PKC substrates 12 h
after treatment with ST022328 are probably the
result of the early inhibition of one or the
inhibition of a combination of the phosphory-
lation of ATM/ATR, AMPK, Akt, and MAPK/CDK
substrates.
DISCUSSION
There has been little progression in developing
new treatments for neuroblastma during the
last few decades, and this is most clearly reflec-
ted by the slow improvement in the 5-year
overall survival of high-risk patients (from 29%
in 1990 to 50% in 2010) [4]. Patients with low-
and intermediate-risk neuroblastoma have
5-year survival rates of 90–100% [4, 19], and
often the first-line treatment of surgical inter-
vention is sufficient in these patients, with
adjuvant chemotherapy restricted to patients
with unreachable tumors, tumors with unfa-
vorable histology, and tumors associated with
genetic aberrations [4, 20]. In high-risk patients,
the options for tumor management include
surgery, multimodal chemotherapy with con-
ventional dosage (induction therapy) followed
by high-dosage chemotherapy combined with
autologous stem cell rescue (consolidation
therapy), external beam radiation therapy, or
immunotherapy [21]. However, these options
do not deliver ideal outcomes to high-risk
neuroblastoma patients: up to 10% of the
patients who reach the criteria to initiate con-
solidation therapy show signs of disease pro-
gression, and even though consolidation
therapy has demonstrated good event-free sur-
vival rates, the overall survival of these patients
remains unchanged [22, 23]. Radiotherapy is
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used as an adjuvant therapy following stem cell
transplant, but even with new technologies that
restrict the exposure of the tumor to radiation
therapy, treating young patients with such
therapies can lead to growth problems or to the
development of other malignancies later in life
[24, 25]. Immunotherapy is another therapeutic
approach that has resulted in successful out-
comes in other cancers. In recent years, anti-PD-
1/PD-L1 or anti-CTLA-4 antibodies have revo-
lutionized cancer therapy for many tumors,
from melanoma to lung cancer [26]—but this
fruitful outcome has not yet reached neurob-
lastoma patients. Only one anti-disialogan-
glioside antibody (dinutuximab) has come on
the market for neuroblastoma patients, and
although this monoclonal antibody has
improved the outcome in high-risk patients, it
is only prescribed to patients who have suc-
cessfully completed both induction and con-
solidation therapies [27].
Kinases have long been recognized to be
important drug targets due to their essential
role in the regulation of virtually all cellular
functions. Since 2001, more than 30 small-
molecule kinase inhibitors have been approved
for the treatment of several diseases, with a
special focus on cancer therapies [28]. However,
although these therapies have revolutionized
the treatment of several cancers, such as BRAF/
MEK inhibitors in melanoma and ALK inhibi-
tors in NSCLC, new targeted inhibitors for
neuroblastoma remain unavailable to clinics.
Efforts are ongoing to use crizotinib, an ALK-
TKI-targeting small-molecule kinase inhibitor
currently used in clinics in the treatment of
NSCLC, for the treatment of ALK-mutated
neuroblastoma patients (ClinicalTrials.gov
Identifier: NCT03126916). However, as
observed in melanoma patients treated with
BRAF and MEK inhibitors, the treatment of
ALK-TKI-mutated NSCLC with crizotinib even-
tually leads to the acquisition of resistance
through the development of secondary muta-
tions in, for example, ALK-TKI or alternative
pathways. In addition, despite second-genera-
tion ALK-TKI-targeting inhibitors, such as alec-
tinib, ceritinib and lorlatinib, having been
developed to circumvent these secondary
mutations in ALK-TKI, it is expected that they
or similar mutations will appear upon the
treatment of neuroblastoma with these same
inhibitors [13, 29]. To overcome these problems
and fill the current lack of therapeutic options,
new alternatives need to be developed that can
be used as single drugs or in combination with
other therapies, namely immunotherapy.
Several studies have been performed in the
search for possible target kinases to be used in
the treatment of neuroblastoma, but very few of
these actually evolved into clinical trials. The
results of a phase I trial on the inhibition of
aurora kinase A in combination with irinotecan
and temozolomide in relapsed or refractory
neuroblastoma patients suggest that this com-
bination has significant anti-tumor activity
[30]. Also, the inhibition of both aurora kinase
A and B appears to provide a relatively stronger
antitumor activity in a panel of neuroblastoma
cell lines with acquired drug resistance, opening
doors for an improved clinical trial [31]. Trials
are currently being carried out on conpalisib, a
phosphatidylinositol-3-kinase inhibitor (Clini-
calTrials.gov Identifier: NCT03458728), and
RAS-MAPK inhibitors (ClinicalTrials.gov Identi-
fier: NCT02124772, NCT02780128, and
NCT03698994) in refractory or relapsed neu-
roblastoma. Interestingly, about 80% of
relapsed neuroblastomas show activating
mutations of the RAS-MAPK pathway, suggest-
ing the important role of this pathway as a
therapeutic target in these tumors [11].
In an effort to identify new small-molecule
kinase inhibitors targeting neuroblastoma, we
performed a high-throughput screening using a
commercially available library of 960 com-
pounds and subsequently identified and vali-
dated 16 compounds with cytotoxic properties
in a larger cohort of neuroblastoma cell lines.
Further evaluation of the effects of two of these
compounds, ST013881 and ST022328, revealed
that they are able to modulate the phosphory-
lation of the Akt, AMPK, ATM/ATR, MAPK/
CDK, PKA, and PKC pathways. ST013881 (2,9-
dimethylpyridino[3,2-h]quinoline), also com-
monly known as neocuproine, has been previ-
ously reported to have cytotoxic properties in
medulloblastoma, melanoma, and breast cancer
cell lines [32–34]. Interestingly, neocuproine
and similar compounds have been described as
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having copper (Cu)(II)-chelating properties, and
the cytotoxic activity of neocuproine has been
attributed to the capacity to form such com-
plexes. In fact, the cytotoxicity of complexes of
Cu(II)-neocuproine is higher than that of cis-
platin in MCF-7 breast cancer cell line [34].
Moreover, Cu(II) has been shown to enhance
the phosphorylation of Erk by Mek1, which can
be reverted by treatment with neocuproine,
affecting the signaling through the MAPK
pathway [35]. The cytotoxic activity we
observed following the treatment of neuroblas-
toma cell lines with neocuproine could be
explained by Cu(II)-neocuproine complexes as
well as by deregulation of the MAPK/CDK
pathway. However, the mechanism of the
cytotoxic activity remains to be fully elucidated.
ST022328 (6-methyl-3-[(2E)-2-(pyridin-2-yl-
methylidene)hydrazinyl]-4H-1,2,4-triazin-5-
one) has been identified as an inhibitor of
ATPase family AAA domain-containing protein
5 (ATAD5) (AID: 504467), bromodomain-adja-
cent to zinc finger domain protein (BAZ2B9)
(AID: 504333), lysine-specific demethylase 4A
(KDM4A) (AID: 504339), and 4D proteins
(KDM4D) (AID: 2147). Interestingly, the results
of one assay, although inconclusive, suggest
that ST022328 might have a role as an activator
of ATM protein (AID: 485349). Reports on yeast
studies reveal that ATAD5 (also known as ELG1)
is important for the regulation of DNA damage
response pathways, namely the ATM/ATR
pathway [36]. It is possible that the inhibition of
ATAD5, as well as of other proteins that regulate
DNA damage response, result in the cytotoxic-
ity observed in neuroblastoma cell lines when
treated with ST022328. Although this study
does not identify specific targets for the com-
pounds analyzed nor addresses in vivo valida-
tion and toxicity, it presents new treatment
possibilities that should be further analyzed in
future studies while shining new light on
important pathways that regulate the develop-
ment and survival of neuroblastomas.
CONCLUSIONS
High-risk neuroblastoma presents a worst out-
come than low- and intermediate-risk
neuroblastoma, mostly due to the inefficient
treatment options. Here we present new com-
pounds for which clinical implications should
be further addressed. We also present an over-
view of kinome alterations induced by these
compounds, opening doors for the study of
these pathways as possible therapeutic targets.
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Disclosures. André Serra-Roma and Olga
Shakhova have nothing to disclose.
Compliance with Ethics Guidelines. Due to
the nature of this research, no ethical approval
was required. The human cell lines used were
commercially available so did not require addi-
tional approval.
Data Availability. All data generated or
analyzed during this study are included in this
published article.
Open Access. This article is licensed under a
Creative Commons Attribution-
Oncol Ther (2020) 8:133–145 143
NonCommercial 4.0 International License,
which permits any non-commercial use, shar-
ing, adaptation, distribution and reproduction
in any medium or format, as long as you give
appropriate credit to the original author(s) and
the source, provide a link to the Creative
Commons licence, and indicate if changes were
made. The images or other third party material
in this article are included in the article’s
Creative Commons licence, unless indicated
otherwise in a credit line to the material. If
material is not included in the article’s Creative
Commons licence and your intended use is not
permitted by statutory regulation or exceeds the
permitted use, you will need to obtain permis-
sion directly from the copyright holder. To view
a copy of this licence, visit http://
creativecommons.org/licenses/by-nc/4.0/.
REFERENCES
1. Heck JE, Ritz B, Hung RJ, Hashibe M, Boffetta P. The
epidemiology of neuroblastoma: a review. Paediatr
Perinat Epidemiol. 2009;23(2):125–43.
2. Matthay KK, Maris JM, Schleiermacher G, et al.
Neuroblastoma. Nat Rev Dis Prim. 2016;2:16078.
https://doi.org/10.1038/nrdp.2016.78.
3. Park JR, Eggert A, Caron H. Neuroblastoma: biology,
prognosis, and treatment. Hematol Oncol Clin
North Am. 2010;24(1):65–866. https://doi.org/10.
1016/j.hoc.2009.11.011.
4. Pinto NR, Applebaum MA, Volchenboum SL, et al.
Advances in risk classification and treatment
strategies for neuroblastoma. J Clin Oncol.
2015;33(27):3008–177. https://doi.org/10.1200/
JCO.2014.59.4648.
5. Park JR, Bagatell R, London WB, et al. Children’s
Oncology Group’s 2013 blueprint for research:
neuroblastoma. Pediatr Blood Cancer. 2013;60(6):
985–93. https://doi.org/10.1002/pbc.24433.
6. Viprey VF, Gregory WM, Corrias MV, et al. Neu-
roblastoma mRNAs predict outcome in children
with stage 4 neuroblastoma: a European HR-NBL1/
SIOPEN study. J Clin Oncol. 2014;32(10):1074–83.
https://doi.org/10.1200/JCO.2013.53.3604.
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